Medical News

RSS

Chiltern International and Charles River Laboratories to study radiolabelled drug products

Chiltern International Limited, a global contract research organization (CRO), announced its latest collaboration with Charles River Laboratories, Inc. As part of this collaboration, Chiltern Early Phase will partner with Charles River to conduct and support early phase radiolabelled studies.

22 Feb 2010

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

Ritter Pharmaceuticals, a company dedicated to helping individuals live a healthier and happier life style through improved digestion, announced today that it will join the leading lactose intolerance experts around the country at the NIH Consensus Development Conference for Lactose Intolerance and Health in Bethesda, Maryland from February 22-24.

22 Feb 2010

FDA grants Fast Track designation for Curemark's CM-AT autism treatment

Curemark LLC, a drug research and development company focused on the treatment of neurological diseases, announced that its CM-AT autism treatment, now in Phase III clinical trials, has been designated as a Fast Track drug by the U.S. Food and Drug Administration (FDA).

22 Feb 2010

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

OrbiMed, a leading investment management firm focused on the healthcare sector, is pleased to announce the launch of its next venture capital fund, Caduceus Private Investments IV, LP, with $550 million in limited partner commitments. Approximately 80% of the new fund’s capital is from returning investors, and the fund’s partners include some of the largest pension plans, endowments, foundations, and sovereign funds globally.

22 Feb 2010

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

BioSante Pharmaceuticals, Inc., today announced additional positive safety data in its ongoing LibiGel Phase III clinical development program. For the second time, unblinded data have been reviewed by the independent DMC of the LibiGel Cardiovascular and Breast Cancer Safety Study. Based on this review, the DMC once again unanimously recommended continuation of the study as described in the FDA-agreed LibiGel safety study protocol, with no modifications.

22 Feb 2010

Obama's health plan to target insurers' rates

President Obama will propose a regulatory crack down on insurers' rate hikes this morning, as the administration seeks to set the stage for a week-long push to reinvigorate the health care debate, The New York Times reports.

22 Feb 2010

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies and therapeutics, is extremely pleased to announce that it has entered into a collaborative agreement with Hadassah Medical Center to conduct its ALS clinical trials at the Hadassah Ein Kerem Hospital.

22 Feb 2010

UIC researchers receive federal grant to study effects of TV media on children’s health outcomes

Researchers at the University of Illinois at Chicago Institute for Health Research and Policy have received a $2.2 million federal grant to determine whether or not TV food advertising affects children's diet, physical activity and weight.

22 Feb 2010

GOP plans to attend health summit as Obama calls for compromise

President Barack Obama warned during the weekend that both Republicans and Democrats should be careful not to turn this week's health care summit into "political theater" but to work to find "common ground" on the issues, The Washington Post reports. "The Thursday event, scheduled to be televised live on C-SPAN, could prove a pivotal moment in the year-long effort to overhaul the health-care system.

22 Feb 2010

Amedica, Orthopaedic Synergy sign SiN articulating hip and knee implant Joint Venture Development Agreement

Amedica Corporation (AC), a spinal and orthopaedic implant and instrument company focused on unique silicon nitride (SiN) ceramic technologies, announced today an agreement with Orthopaedic Synergy, Inc. (OSI), a holding company for OMNIlife Science™ and Enztec, both global designers, manufacturers and distributors of leading edge reconstructive surgery implants and instrumentation.

22 Feb 2010

Insurers rebut criticisms of profits, rates

As the Obama Administration seizes on a proposed 39-percent rate hike by a California insurer earlier this month to rally new support for a health overhaul, that insurer's top executive is preparing to go before Congress, The Associated Press/Los Angeles Times reports.

22 Feb 2010

Full text: Obama's health care proposal

Kaiser Health News reports the "proposal President Barack Obama will bring to his Thursday health 'summit' with Congressional leaders contains many of the ideas from the bills already passed by the Democratic House and Senate, including a mandate that individuals buy insurance and a promise to 'end discrimination' from pre-existing conditions."

22 Feb 2010

NHMRC awards $12.7 million for malaria research

A research program that aims to better understand malaria infection and develop treatments and vaccines for the disease has today been awarded $12.7 million (US$11.5 million) by Australia's National Health and Medical Research Council (NHMRC).

22 Feb 2010

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

The U.S. Food and Drug Administration approved an important new inhaled antibiotic called Cayston® (aztreonam for inhalation solution) today for the treatment of cystic fibrosis. The drug was made possible by significant support from the Cystic Fibrosis Foundation, including a $1 million investment by a Foundation subsidiary to help develop the therapy.

22 Feb 2010

U.S. HealthWorks expands its footprint in Arizona by acquiring three healthcare centers

U.S. HealthWorks, a leading operator of occupational healthcare centers in the nation, today announced the acquisition of all three Tucson Occupational Medicine healthcare centers.

22 Feb 2010

VA focuses on female veterans' struggles, disability claims backlog

News outlets explore issues at the Department of Veterans Affairs, which is seeking to cut a backlog in disability claims and also address the needs of female veterans.

22 Feb 2010

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Boehringer Ingelheim Pharmaceuticals, Inc., today announced that the U.S. Food and Drug Administration (FDA) has approved Mirapex ER® (pramipexole dihydrochloride) extended-release tablets, a new once-daily treatment option for the signs and symptoms of early idiopathic Parkinson's disease (PD). MIRAPEX ER is not indicated in advanced PD. Parkinson's disease is a chronic, slowly progressive and potentially debilitating neurological condition affecting nearly one million people in the U.S., with one person newly diagnosed every nine minutes.

22 Feb 2010

Governors on health reform: 'We want in'

"Some governors, frustrated by halted federal efforts to overhaul the U.S. health-care system" and by lingering budget shortfalls deepened by rising health costs, "are introducing their own changes at the state level," The Wall Street Journal reports. While some states, such as Massachusetts, have already taken on health care, others, such as Colorado, Pennsylvania and Republican-led Utah, are now tackling the issues, including cost. "Some governors suggested they may be better equipped to work with one another on health care than congressional leaders who have been at an impasse over federal legislation" (Thiruvengadam, 2/22).

22 Feb 2010

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has initiated a Phase IIb trial in adult lung transplant patients with ALN-RSV01, an RNAi therapeutic for the treatment of respiratory syncytial virus (RSV) infection. RSV infection in lung transplant patients represents an important unmet medical need; the condition is associated with significant morbidity, including the development of acute lung transplant rejection in 10% to 20% of infected patients.

22 Feb 2010

First Edition: February 22, 2010

Peter Orszag, director of the White House Office of Management and Budget, tells POLITICO that it is "absolutely" still possible to pass a comprehensive health reform bill, insisting that "to really reform the health care system" would be "best for the economy and the American public" (Politico).

22 Feb 2010

Medical News

Chiltern International and Charles River Laboratories to study radiolabelled drug products

Ritter Pharmaceuticals to discuss lactose intolerance and associated health risks at NIH Conference

FDA grants Fast Track designation for Curemark's CM-AT autism treatment

OrbiMed announces next venture capital fund for investments in biopharmaceutical and medical device companies

BioSante Pharmaceuticals' ongoing LibiGel Phase III clinical development program: Additional positive data

Obama's health plan to target insurers' rates

BrainStorm Cell Therapeutics, Hadassah Medical Center sign collaborative agreement for ALS clinical trials

UIC researchers receive federal grant to study effects of TV media on children’s health outcomes

GOP plans to attend health summit as Obama calls for compromise

Amedica, Orthopaedic Synergy sign SiN articulating hip and knee implant Joint Venture Development Agreement

Insurers rebut criticisms of profits, rates

Full text: Obama's health care proposal

NHMRC awards $12.7 million for malaria research

Gilead Sciences receives FDA approval for new inhaled antibiotic in treatment of CF

U.S. HealthWorks expands its footprint in Arizona by acquiring three healthcare centers

VA focuses on female veterans' struggles, disability claims backlog

Boehringer Ingelheim Pharmaceuticals receives FDA approval for Mirapex ER in treatment of early PD

Governors on health reform: 'We want in'

Alnylam Pharmaceuticals initiates ALN-RSV01 Phase IIb trial in adult lung transplant patients for RSV infection

First Edition: February 22, 2010

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Latest News